153 related articles for article (PubMed ID: 22820565)
1. 16,17-Dihydro-17b-hydroxy isomitraphylline alkaloid as an inhibitor of DPP-IV, and its effect on incretin hormone and β-cell proliferation in diabetic rat.
Shukla A; Srinivasan BP
Eur J Pharm Sci; 2012 Sep; 47(2):512-9. PubMed ID: 22820565
[TBL] [Abstract][Full Text] [Related]
2. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
Akarte AS; Srinivasan BP; Gandhi S
Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
[TBL] [Abstract][Full Text] [Related]
3. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
Akarte AS; Srinivasan BP; Gandhi S
J Diabetes Complications; 2012; 26(4):266-74. PubMed ID: 22626875
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase-4 inhibition in diabetic rats leads to activation of the transcription factor CREB in β-cells.
Pugazhenthi S; Qin L; Bouchard R
Eur J Pharmacol; 2015 May; 755():42-9. PubMed ID: 25720341
[TBL] [Abstract][Full Text] [Related]
5. Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes.
Yang SJ; Choi JM; Kim L; Kim BJ; Sohn JH; Kim WJ; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Kim SW; Park CY
Biochem Biophys Res Commun; 2011 Apr; 407(1):153-7. PubMed ID: 21371430
[TBL] [Abstract][Full Text] [Related]
6. Improved outcome of islet transplantation in partially pancreatectomized diabetic mice by inhibition of dipeptidyl peptidase-4 with sitagliptin.
Kim YS; Oh SH; Park KS; No H; Oh BJ; Kim SK; Jung HS; Kim JH; Lee MS; Lee MK; Kim KW
Pancreas; 2011 Aug; 40(6):855-60. PubMed ID: 21747318
[TBL] [Abstract][Full Text] [Related]
7. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
[TBL] [Abstract][Full Text] [Related]
8. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
Chang E; Kim L; Choi JM; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park DI; Park CY
Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082
[TBL] [Abstract][Full Text] [Related]
9. Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin.
Akarte AS; Srinivasan BP; Gandhi S
Eur J Pharm Sci; 2012 Apr; 45(5):546-51. PubMed ID: 22155545
[TBL] [Abstract][Full Text] [Related]
10. Anti-diabetic effects of Centratherum anthelminticum seeds methanolic fraction on pancreatic cells, β-TC6 and its alleviating role in type 2 diabetic rats.
Arya A; Looi CY; Cheah SC; Mustafa MR; Mohd MA
J Ethnopharmacol; 2012 Oct; 144(1):22-32. PubMed ID: 22954496
[TBL] [Abstract][Full Text] [Related]
11. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
12. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
[TBL] [Abstract][Full Text] [Related]
13. Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice.
Furuta Y; Horiguchi M; Sugaru E; Ono-Kishino M; Otani M; Sakai M; Masui Y; Tsuchida A; Sato Y; Takubo K; Hochigai H; Kimura H; Nakahira H; Nakagawa T; Taiji M
Diabetes Obes Metab; 2010 May; 12(5):421-30. PubMed ID: 20415690
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces β-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice.
Suarez-Pinzon WL; Rabinovitch A
Cell Transplant; 2011; 20(9):1343-9. PubMed ID: 21396168
[TBL] [Abstract][Full Text] [Related]
15. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.
Cho JM; Jang HW; Cheon H; Jeong YT; Kim DH; Lim YM; Choi SH; Yang EK; Shin CY; Son MH; Kim SH; Kim HJ; Lee MS
Diabetes Res Clin Pract; 2011 Jan; 91(1):72-9. PubMed ID: 21093089
[TBL] [Abstract][Full Text] [Related]
16. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
17. Effects of an olive oil-enriched diet on glucagon-like peptide 1 release and intestinal content, plasma insulin concentration, glucose tolerance and pancreatic insulin content in an animal model of type 2 diabetes.
Cancelas J; Prieto PG; Villanueva-Peñacarrillo ML; Valverde I; Malaisse WJ
Horm Metab Res; 2006 Feb; 38(2):98-105. PubMed ID: 16523410
[TBL] [Abstract][Full Text] [Related]
18. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats.
Duttaroy A; Voelker F; Merriam K; Zhang X; Ren X; Subramanian K; Hughes TE; Burkey BF
Eur J Pharmacol; 2011 Jan; 650(2-3):703-7. PubMed ID: 21070766
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
[TBL] [Abstract][Full Text] [Related]
20. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]